

NATIONAL INSTITUTE ON DRUG ABUSE

MEDICATIONS DEVELOPMENT

FUNDING OPPORTUNITIES

The Division of Treatment Research and Development supports an infrastructure of identification, evaluation, and development of medications for the treatment of drug dependence. A major initiative of the medications development program is the discovery of new pharmacotherapies for cocaine, methamphetamine (and other stimulants), and opiate dependence. Programmatic interests concentrate on applied research directed toward the goal of developing pharmacotherapeutic products.

PROGRAMMATIC FUNDING OPPORTUNITIES:

- ! **Medicinal chemistry** to design and synthesize new chemical entities with potential for use as cocaine, methamphetamine and opioid (primarily kappa antagonists) dependence pharmacotherapies.
- ! **Preclinical compound screening and pharmacodynamic profiling efforts** targeted toward the discovery of medications for treating all aspects of drug dependence.
- ! **Development of innovative preclinical (*in vitro* or *in vivo*) methods** for the characterization of potential treatment agents for the entire spectrum of drug dependency (addiction, abstinence, relapse and recovery). Priority is given to the development of cocaine and/or opiate "craving" and relapse models, and assays to measure antagonism.
- ! **Development of biopharmaceutical information** including blood brain barrier permeability.
- ! **Metabolism and pharmacokinetic studies**, including modeling.
- ! **Clinical Research** on translating advanced preclinical and/or basic research findings of treatment therapeutics or strategies into clinical "proof of concept" testing.

RESOURCES AVAILABLE TO INVESTIGATORS:

- ! **Preclinical screening** of new compounds for use as cocaine and opiate dependence pharmacotherapies. These include *in vitro* opiate receptor subtype assays, *in vitro* biogenic amine receptor/transporter assays, *in vivo* locomotor activity studies, rat and primate drug self-administration studies and rat and primate drug discrimination studies.
- ! **Scale-up synthesis (non-GMP and GMP)** of compounds from drug abuse investigators for preclinical and clinical studies.
- ! **Toxicological** and safety assessment evaluation.
- ! **Pharmacokinetic** and pharmacodynamic studies.
- ! **Dosage form development.**
- ! **Analytical chemistry services.**
- ! **Clinical trials.**

For details please contract:

Medicinal Chemistry:
Jamie Biswas, Ph.D.
301-443-8096
jb168r@nih.gov

Toxicology:
James Terrill, Ph.D.
301-443-8289
jt62r@nih.gov

Pharmacokinetics & Pharmaceutics:
Nora Chiang, Ph.D.
301-443-5280
nchiang@nih.gov

Clinical Studies:
Betty Tai, Ph.D.
301-443-2397
Btai@nih.gov

Animal Models & Pharmacological Screening:
Jane B. Acri, Ph.D.
301-443-8489
Jacri@nih.gov